R. Bell

发表

5‐Lipoxygenase Inhibitors: Synthesis and Structure‐Activity Relationships of a Series of 1‐Aryl‐2H,4H‐tetrahydro‐1,2,4‐triazin‐3‐ ones.

P. Young, B. Gunn, J. Bouska, 1997 .

Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605

S. Davidsen, Eric F. Johnson, N. Soni, 2009, BMC Cancer.

Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor

Qian Zhang, L. Tucker, Jieyi Wang, 2008, Proceedings of the National Academy of Sciences.

Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding.

Scott A. Erickson, S. Davidsen, A. Petros, 2006, Journal of medicinal chemistry.

The enzymology and pharmacology of 5-lipoxygenase and 5-lipoxygenase activating protein

R. Bell, R. Harris, 1999, Clinical reviews in allergy & immunology.

The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep.

J. Bouska, W. Abraham, C. Lanni, 1992, European journal of pharmacology.

ZILEUTON : THE FIRST LEUKOTRIENE SYNTHESIS INHIBITOR FOR USE IN THE MANAGEMENT OF CHRONIC ASTHMA

L. Dubé, L. Swanson, G. Carter, 1998 .

The development of zileuton (ZYFLO ® ) and the N-hydroxyurea class of 5-lipoxygenase inhibitors

R. Bell, 1999 .

Chapter 9. Leukotriene Modulators as Therapeutic Agents in Asthma and Other Inflammatory Diseases

J. Summers, R. Bell, R. Harris, 1997 .

Clinical activity of leukotriene inhibitors.

D. W. Brooks, G. Carter, R. Harris, 1995, International journal of immunopharmacology.

Pharmacological modulation of eosinophil influx into the lungs of Brown Norway rats.

C. Goodfellow, G. Carter, R. Harris, 1996, European journal of pharmacology.

Preclinical and Clinical Activity of Zileuton and A‐78773

R. Hansen, D. W. Brooks, G. Carter, 1993, Annals of the New York Academy of Sciences.

The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.

J. Summers, D. W. Brooks, G. Carter, 1994, Pulmonary pharmacology.

Characterization of A-93178, an Iminoxy-Quinoline

J. Bouska, G. Carter, K. Hulkower, 1997 .

Identification and Characterization of Novel Antagonists of the CCR3 Receptor

L. Traphagen, U. Warrior, D. Burns, 2003, Journal of biomolecular screening.

The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.

P. Young, D. Albert, J. Summers, 1992, International journal of immunopharmacology.

Stimulus dependence of non-steroidal antiinflammatory drug potency in a cellular assay of prostaglandin H synthase-2.

A. Wernimont, K. Hulkower, R. Bell, 1997, European journal of pharmacology.

Stereoselective Metabolism of the 5‐Lipoxygenase Inhibitor A‐78773

L. Dubé, R. Hansen, J. Bouska, 1994, Annals of the New York Academy of Sciences.

ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents.

J. Bouska, G. Carter, K. Hulkower, 1997, The Journal of pharmacology and experimental therapeutics.

Conversion of cyclooxygenase inhibitors into hydroxythiazole 5-lipoxygenase inhibitors.

J. Bouska, K. Hulkower, F. A. Kerdesky, 1997, Bioorganic & medicinal chemistry.

Bradykinin-stimulated release of arachidonate from phosphatidyl inositol in mouse fibrosarcoma cells.

P. Majerus, R. Bell, N. Baenziger, 1980, Prostaglandins.

Thrombin-induced hydrolysis of phosphatidylinositol in human platelets.

P. Majerus, R. Bell, 1980, The Journal of biological chemistry.

Chapter 8. Pulmonary and Antiallergy Agents

D. W. Brooks, G. Carter, R. Bell, 1988 .

The properties of A-69412: A small hydrophilic 5-lipoxygenase inhibitor

P. Young, J. Summers, J. Bouska, 2005, Agents and Actions.

Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.

J. Bouska, D. W. Brooks, G. Carter, 1995, The Journal of pharmacology and experimental therapeutics.

Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay.

C. Goodfellow, G. Carter, J. Bouska, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors.

J. Bouska, K. Hulkower, R. Harris, 1997, Bioorganic & medicinal chemistry.

Changes in order of migration of polypeptides in complex III and cytochrome C oxidase under different conditions of SDS polyacrylamide gel electrophoresis.

T. Branchek, R. Capaldi, R. Bell, 1977, Biochemical and biophysical research communications.

Inhibition of leukotriene biosynthesis in the rat peritoneal cavity.

P. Young, J. Summers, D. W. Brooks, 1991, European journal of pharmacology.

O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors

R. Maki, P. Young, J. Bouska, 1996 .

A-78773: a selective, potent 5-lipoxygenase inhibitor.

P. Young, J. Bouska, D. W. Brooks, 1993, Journal of lipid mediators.

Components of the mitochondrial inner membrane. 2. The polypeptide composition of ubiquinone-cytochrome c reductase (complex III) from beef heart mitochondria

R. Capaldi, R. Bell, 1976 .

Induction of prostaglandin H synthase-2 and tumor necrosis factor-alpha in human amnionic WISH cells by various stimuli occurs through distinct intracellular mechanisms.

K. Glaser, G. Carter, K. Hulkower, 1997, The Journal of pharmacology and experimental therapeutics.

Leukotrienes do not regulate nitric oxide production in RAW 264.7 macrophages.

J. Pollock, K. Hulkower, C. Brooks, 1996, Prostaglandins, leukotrienes, and essential fatty acids.

Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.

S. Badylak, F. Haviv, J. Henkin, 2005, Journal of medicinal chemistry.

Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.

S. Davidsen, Eric F. Johnson, J. Wilsbacher, 2010, Bioorganic & medicinal chemistry letters.

Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties.

Scott A. Erickson, K. Comess, A. Vasudevan, 2006, Bioorganic & medicinal chemistry letters.

Lysyl 4-aminobenzoic acid derivatives as potent small molecule mimetics of plasminogen kringle 5.

J. Henkin, D. Davidson, G. Sheppard, 2004, Bioorganic & medicinal chemistry letters.

Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR).

S. Davidsen, Eric F. Johnson, J. Wilsbacher, 2007, Bioorganic & medicinal chemistry letters.

ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor

G. Carter, S. Surapaneni, K. Marsh, 2004, Journal of Pharmacology and Experimental Therapeutics.

Synthesis of 4,5-diaryl-1H-pyrazole-3-ol derivatives as potential COX-2 inhibitors.

R. Henry, R. Bell, T. Kolasa, 2004, The Journal of organic chemistry.

Design of inhibitors of leukotriene biosynthesis and their therapeutic potential

J. Bouska, G. Carter, R. Harris, 1998 .

Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.

R. Maki, P. Young, J. Summers, 1997, Journal of medicinal chemistry.

Diglyceride lipase: a pathway for arachidonate release from human platelets.

P. Majerus, D. Kennerly, R. Bell, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis.

J. Bouska, G. Carter, K. Hulkower, 2000, Journal of medicinal chemistry.

Lead optimization of methionine aminopeptidase-2 (MetAP2) inhibitors containing sulfonamides of 5,6-disubstituted anthranilic acids.

Gary T. Wang, Chang H. Park, Jieyi Wang, 2007, Bioorganic & medicinal chemistry letters.

Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction

L. Matrisian, R. DuBois, D. Morgan, 2003, British Journal of Cancer.

Mediators of C5a-induced bronchoconstriction in the guinea pig.

R. Bell, J. Regal, 1987, International archives of allergy and applied immunology.

The role of tissue mast cells in polyacrylamide gel-induced inflammation in mice

G. Carter, D. Wilcox, R. Harris, 1998, Inflammation Research.

Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation

S. Davidsen, Qian Zhang, L. Tucker, 2008, Oncogene.

Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.

Scott A. Erickson, S. Davidsen, K. Swinger, 2010, Bioorganic & medicinal chemistry letters.

Labeling of complex III, with [35S]diazobenzenesulfonate: orientation of this electron transfer segment in the mitochondrial inner membrane.

R. Capaldi, B. Ludwig, R. Bell, 1979, Proceedings of the National Academy of Sciences of the United States of America.

LABELLING OF COMPLEX III WITH 35S DIAZOBENZENESULFONATE. ORIENTATION OF THIS ELECTRON TRANSFER SEGMENT IN THE MITOCHONDRIAL INNER MEMBRANE

R. Capaldi, B. Ludwig, R. Bell, 1978 .

4-hydroxythiazole inhibitors of 5-lipoxygenase.

R. D. Dyer, R. Dyer, D. W. Brooks, 1991, Journal of medicinal chemistry.

5-lipoxygenase inhibitory activity of zileuton.

R. D. Dyer, P. Young, D. Albert, 1991, The Journal of pharmacology and experimental therapeutics.

Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.

J. Summers, J. Bouska, G. Carter, 1997, Journal of medicinal chemistry.

Thiazole analogues of the NSAID indomethacin as selective COX-2 inhibitors.

M. Michaelides, K. Hulkower, K. Woods, 2001, Bioorganic & medicinal chemistry letters.

5-Lipoxygenase inhibitors: synthesis and structure-activity relationships of a series of 1-aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.

P. Young, B. Gunn, J. Bouska, 1996, Journal of medicinal chemistry.

Contribution of macrophages to immediate hypersensitivity reaction.

R. Bell, B. Jakschik, Y. Wei, 1986, Journal of immunology.

Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation*

S. Davidsen, J. Wilsbacher, Gary T. Wang, 2008, Journal of Biological Chemistry.

COX-2 Inhibitors and Leukotriene Modulators

R. Bell, A. Stewart, R. Harris, 2003 .

Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.

J. Bouska, G. Carter, K. Hulkower, 2000, Journal of medicinal chemistry.

(R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.

J. Bouska, G. Carter, P. Bhatia, 1995, Journal of medicinal chemistry.

Diglyceride lipase: a pathway for arachidonate release from human platelets.

P. Majerus, D. Kennerly, R. Bell, 1980, Advances in prostaglandin and thromboxane research.

Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.

Scott A. Erickson, S. Davidsen, Eric F. Johnson, 2009, Bioorganic & medicinal chemistry letters.

Discovery, identification, and characterization of candidate pharmacodynamic markers of methionine aminopeptidase-2 inhibition.

S. Davidsen, P. Richardson, Qian Zhang, 2008, Journal of proteome research.

Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor

Qian Zhang, L. Tucker, Jieyi Wang, 2008, Proceedings of the National Academy of Sciences.

ABT-963, A Highly Potent and Selective Disubstituted Pyridazinone COX-2 Inhibitor

G. Carter, S. Surapaneni, M. Jarvis, 2004 .